BTAI BioXcel Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BTAI

Price (delayed)

$2.57

Market cap

$78.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.15

Enterprise value

$114.4M

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically ...

Highlights
BTAI's revenue is up by 11% since the previous quarter
BTAI's quick ratio has dropped by 59% year-on-year but it is up by 3.9% since the previous quarter
BTAI's EPS is up by 16% since the previous quarter but it is down by 3.9% year-on-year
The equity has dropped by 174% year-on-year and by 39% since the previous quarter
BTAI's gross margin has dropped by 91% year-on-year and by 84% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.bioxceltherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of BTAI
Market
Shares outstanding
30.58M
Market cap
$78.58M
Enterprise value
$114.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
54.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
82.9
Earnings
Revenue
$1.38M
EBIT
-$165.74M
EBITDA
-$165.42M
Free cash flow
-$155.03M
Per share
EPS
-$6.15
Free cash flow per share
-$5.32
Book value per share
-$1.93
Revenue per share
$0.05
TBVPS
$2.53
Balance sheet
Total assets
$73.7M
Total liabilities
$130.21M
Debt
$101.04M
Equity
-$56.51M
Working capital
$44.88M
Liquidity
Debt to equity
-1.79
Current ratio
2.65
Quick ratio
2.39
Net debt/EBITDA
-0.22
Margins
EBITDA margin
-11,987%
Gross margin
8.7%
Net margin
-12,974.9%
Operating margin
-12,448%
Efficiency
Return on assets
-144.9%
Return on equity
N/A
Return on invested capital
-214%
Return on capital employed
-356.9%
Return on sales
-12,010.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BTAI stock price

How has the BioXcel Therapeutics stock price performed over time
Intraday
0.39%
1 week
-2.28%
1 month
-2.65%
1 year
-88.49%
YTD
-12.88%
QTD
-8.87%

Financial performance

How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$1.38M
Gross profit
$120,000
Operating income
-$171.78M
Net income
-$179.05M
Gross margin
8.7%
Net margin
-12,974.9%
BTAI's gross margin has dropped by 91% year-on-year and by 84% since the previous quarter
The gross profit has plunged by 83% from the previous quarter and by 66% YoY
BTAI's operating margin has soared by 71% YoY and by 25% QoQ
BTAI's net margin has surged by 71% year-on-year and by 24% since the previous quarter

Growth

What is BioXcel Therapeutics's growth rate over time

Valuation

What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
54.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
82.9
BTAI's EPS is up by 16% since the previous quarter but it is down by 3.9% year-on-year
The equity has dropped by 174% year-on-year and by 39% since the previous quarter
The price to sales (P/S) is 82% lower than the last 4 quarters average of 307.1
BTAI's revenue is up by 11% since the previous quarter

Efficiency

How efficient is BioXcel Therapeutics business performance
BioXcel Therapeutics's return on assets has shrunk by 99% YoY and by 7% QoQ
BTAI's return on sales has surged by 71% year-on-year and by 25% since the previous quarter
BioXcel Therapeutics's ROIC has increased by 30% YoY and by 19% from the previous quarter

Dividends

What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BTAI.

Financial health

How did BioXcel Therapeutics financials performed over time
The total assets is 43% less than the total liabilities
The total assets has plunged by 64% YoY and by 27% from the previous quarter
BTAI's quick ratio has dropped by 59% year-on-year but it is up by 3.9% since the previous quarter
The equity has dropped by 174% year-on-year and by 39% since the previous quarter
BioXcel Therapeutics's debt to equity has increased by 27% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.